NPM1-mutated AML is categorized as favorable risk when FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) is absent, according to the 2022 ELN classification [41,42]. This evidence concerns the gene FLT3 and acute myeloid leukemia.